An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) will announce its First Quarter 2024 Financial Results on May 8, 2024. The global medical technology company focuses on women's health and wellness, particularly in breast aesthetics and reconstruction. The conference call to discuss the results will be held at 4:30 pm ET on the same day.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) annuncerà i suoi risultati finanziari del primo trimestre 2024 l'8 maggio 2024. L'azienda globale di tecnologia medica si concentra sulla salute e il benessere delle donne, in particolare nell'estetica e ricostruzione del seno. La conferenza telefonica per discutere i risultati si terrà alle 16:30 ET dello stesso giorno.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) anunciará sus resultados financieros del primer trimestre del 2024 el 8 de mayo de 2024. La compañía global de tecnología médica se centra en la salud y el bienestar de las mujeres, especialmente en la estética y reconstrucción mamaria. La llamada de conferencia para discutir los resultados se realizará a las 4:30 p.m. ET ese mismo día.
Establishment Labs Holdings Inc. (NASDAQ: ESTA)는 2024년 5월 8일에 2024년 1분기 재무 결과를 발표할 예정입니다. 이 글로벌 의료 기술 회사는 특히 유방 미학 및 재건에 중점을 두고 여성의 건강과 웰빙에 중점을 둡니다. 결과를 논의하기 위한 전화 회의는 같은 날 오후 4시 30분 ET에 열릴 예정입니다.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) annoncera ses résultats financiers pour le premier trimestre 2024 le 8 mai 2024. Cette entreprise mondiale de technologie médicale se concentre sur la santé et le bien-être des femmes, notamment dans les domaines de l'esthétique et de la reconstruction mammaire. La conférence téléphonique pour discuter des résultats aura lieu à 16h30 ET le même jour.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) wird am 8. Mai 2024 die finanziellen Ergebnisse für das erste Quartal 2024 bekannt geben. Das weltweit tätige Medizintechnikunternehmen konzentriert sich auf Gesundheit und Wohlbefinden von Frauen, insbesondere auf Brustästhetik und -rekonstruktion. Die Telefonkonferenz zur Besprechung der Ergebnisse findet am selben Tag um 16:30 ET statt.
Positive
None.
Negative
None.
NEW YORK--(BUSINESS WIRE)--
Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended March 31, 2024 after the market closes on Wednesday, May 8, 2024, and will host a conference call at 4:30 pm ET that day to discuss those results.
To participate in the conference call, dial (877) 407-8037 (U.S. and Canada) or +1 (201) 689-8037 (International) and use conference ID number 13746251. The call will also be available via live or archived webcast on the “Investor Relations” section of the Establishment Labs website at www.establishmentlabs.com.
About Establishment Labs
Establishment Labs Holdings Inc. is a global medical technology company dedicated to improving women’s health and wellness through the power of science, engineering, and technology. The Company offers a portfolio of Femtech solutions for breast health, breast aesthetics and breast reconstruction. The over three million Motiva® devices Establishment Labs has delivered to plastic and reconstructive surgeons since 2010 have created a new standard for safety and patient satisfaction in the over 85 countries in which they are available. The Motiva Flora® tissue expander is used to improve outcomes in breast reconstruction following breast cancer and it is the only regulatory-approved expander in the world with an integrated port using radio-frequency technology that is MRI conditional. Mia Femtech™, Establishment Lab’s unique minimally invasive experience for breast harmony, is the Company’s most recent breakthrough innovation. These solutions are supported by over 200 patent applications in 25 separate patent families worldwide and over 50 scientific studies and publications in peer reviewed journals. Establishment Labs manufactures at two facilities in Costa Rica compliant with all applicable regulatory standards under ISO13485:2016 and FDA 21 CFR 820 under the MDSAP program. In 2018, the Company received an investigational device exemption (IDE) from the FDA for Motiva Implants® and began a clinical trial to support regulatory approval in the United States. Please visit our website for additional information at www.establishmentlabs.com.
When will Establishment Labs announce its First Quarter 2024 Financial Results?
Establishment Labs will announce its First Quarter 2024 Financial Results on May 8, 2024.
What is the ticker symbol for Establishment Labs?
The ticker symbol for Establishment Labs is ESTA.
Where can I listen to the conference call discussing the financial results?
You can listen to the conference call discussing the financial results on the 'Investor Relations' section of the Establishment Labs website at www.establishmentlabs.com.
establishment labs is a global, privately held, high-tech medical device and aesthetics company that designs, develops, manufactures and markets an innovative product portfolio consisting of advanced silicone-filled breast and body shaping implants. with more than 30 years of advanced breast implant manufacturing experience, building quality breast implants has always been a natural outcome for establishment labs’ founders and top executives. as a result, motiva implants® has established a level of product innovation that always results in safety. and while we respect our past, we ́re more focused on the present and the future, one that ́s innovative, safe and progressive. we believe that these goals can be achieved by incorporating the current needs and preferences of plastic surgeons and patients into our product design.
